How are topical anticholinergic creams (e.g., glycopyrrolate) used to treat focal primary hyperhidrosis?

Topical Anticholinergic Creams for Focal Primary Hyperhidrosis

Topical glycopyrrolate (glycopyrronium) is the first-line pharmacological treatment for moderate to severe primary axillary hyperhidrosis that has failed topical antiperspirants, with FDA-approved formulations demonstrating significant sweat reduction and quality of life improvements. 1, 2

Mechanism and Formulations

Glycopyrrolate is a quaternary ammonium anticholinergic that blocks acetylcholine at muscarinic receptors in eccrine sweat glands, reducing sweat production 3. Its highly polar structure limits systemic absorption across lipid membranes, minimizing central nervous system effects compared to tertiary amines like atropine 3.

FDA-approved formulations:

• Glycopyrronium tosylate 3.75% cloth (Qbrexza™) - approved for patients ≥9 years 4, 5
• Glycopyrronium bromide 1% cream - demonstrated efficacy in phase III trials 6

Clinical Efficacy

The evidence is robust, with multiple phase III randomized controlled trials enrolling over 2,000 patients:

Axillary hyperhidrosis outcomes:

• Responder rates: 59.5% achieved ≥4-point improvement on sweating severity scales vs 27.6% with vehicle (p<0.001) 4
• Sweat reduction: Mean reduction of 107.6 mg/5 min vs 92.1 mg/5 min with vehicle 4
• Quality of life: HidroQoL improvement exceeded minimal clinically important difference, with 60% responders vs 26% placebo 6
• HDSS improvement: 2.33-fold higher responder rate compared to placebo 7

Long-term data: Efficacy maintained through 44-48 weeks of continuous use, with 63.2% HDSS responder rate at week 44 5

Application Protocol

For axillary hyperhidrosis:

• Apply once daily to each axilla
• Continue for minimum 4 weeks to assess response 6, 4
• Can be used long-term with maintained efficacy 5

For palmar hyperhidrosis (off-label):

• 30 minutes without occlusion produces optimal results 8
• Avoid occlusion - increases sweating and dilutes medication 8
• 15-minute application less effective; overnight application not superior to 30 minutes 8

Safety Profile

The treatment is generally well-tolerated with predominantly mild-to-moderate adverse effects:

Common adverse events:

• Dry mouth: 16-17% (expected anticholinergic effect) 6, 5
• Blurred vision: 6.7% 5
• Mydriasis: 5.3% 5
• Application-site reactions: 9% (mild/moderate, transient) 6

Critical safety considerations:

• Warn patients explicitly about eye contact - unilateral mydriasis occurs from inadvertent introduction into eyes 8
• Most local skin reactions (67.5% had none) were mild/moderate when present 5
• Discontinuation rate due to adverse events: 8% over 44 weeks 5
• Systemic absorption minimal due to quaternary structure 3

Cumulative discontinuation remained stable at 8% over 44 weeks, indicating acceptable long-term tolerability 5

Treatment Algorithm

1. First-line: Topical antiperspirants for mild hyperhidrosis
2. First-line pharmacological: Topical glycopyrrolate 3.75% cloth or 1% cream for moderate-to-severe disease uncontrolled by antiperspirants 1, 2
3. Second-line: Botulinum toxin injections, microwave treatment, or oral anticholinergics 1, 2

Clinical Pitfalls

• Do not combine with occlusion for palmar treatment - paradoxically reduces efficacy 8
• Counsel extensively on avoiding eye contact - most preventable adverse event 8
• Allow 4-week trial minimum before declaring treatment failure 6
• Do not use topical antihistamines - insufficient evidence for efficacy in hyperhidrosis and risk of contact dermatitis 9

Comparative Effectiveness

Topical glycopyrrolate 2% demonstrated equivalent efficacy to botulinum toxin type A injections for axillary hyperhidrosis, offering a non-invasive alternative 10. The 1% concentration showed less improvement than botulinum toxin but still significant benefit 10.